OREANDA-NEWS. On November 20, German pharmaceutical company BioNTech and its American partner Pfizer filed an application with the US Food and Drug Administration to register a vaccine against coronavirus of a new type. This is stated in a press release distributed by BioNTech.

Applying for authorization to use the medication in emergency cases in the United States is an important step towards making candidate vaccine available to the world’s population as soon as possible, Ugur Sahin, CEO and co-founder of BioNTech, said.

The company’s representatives added that BioNTech and Pfizer have already begun filing applications with regulatory authorities around the world, for instance in the European Union and Great Britain.

Both enterprises previously reported their vaccine offers 95 % protection against COVID-19. It is known that the new drug belongs to a group of so called gene vaccines that contain genetic information about the pathogen.